RESUMO
BackgroundAdolescents and young adults might play a key role in the worldwide spread of Coronavirus Disease 2019 (COVID-19), because they are more involved in overseas studying, business, working, and travelling. However, the epidemiological and clinical characteristics of them are still unknown. MethodsWe collected data of 46 confirmed COVID-19 patients aged 10 to 35 years from the study hospital. The demographics, epidemiological, and clinical data were collected. Several key epidemiological parameters, the asymptomatic cases and transmission to their family members and the clinical characteristics at admission, and during treatment were summarized. RESULTSOf 46 confirmed patients, 14 patients (47.3%) were aged from 10 to 24 years, and 24 (52.7%) patients were male. The mean incubation period for symptomatic cases was 6.6 days (95% confidence interval (CI) 4.4 - 9.6). The median serial interval was 1.9 days (95% CI 0.4 - 6.2). Three of asymptomatic cases showed the transmission to their family members. Only 1 patient was identified as severe cases at admission. The common symptoms at admission were dry cough (34, 91.0%), and fever (29, 69.0%). Nearly 60% of the patients had showed ground-glass opacity by chest CT findings. Three patients developed acute kidney injury during treatment. Majority of patients (78.3%) were discharged by the end of the follow-up. ConclusionsThe adolescent and young adult patients of COVID-19 had a long incubation period, and a short serial interval. The transmission to their family contactors occurred in asymptomatic cases. Few of the study patients have developed complications during treatment.
RESUMO
OBJECTIVE: To investigate the effects of rosuvastatin combined with tirofiban on serum inflammatory factors and renal function in acute coronary syndrome patients with diabetes after percutaneous coronary intervention (PCI).METHODS: A total of 120 acute coronary syndrome patients with diabetes receiving PCI selected from cardiology department of our hospital during Apr. 2014-Mar. 2015 were divided into control group and observation group according to random number table, with 60 cases in each group. Except for routine treatment, control group was given Rosuvastatin calcium tablets orally after surgery (10 mg each day, for consecutive 7 d); observation group was given Rosuvastatin calcium tablets orally before and after surgery (20 mg before surgery; 10 mg each day after surgery, for consecutive 7 d), and then given Tirohydrochloric acid sodium chloride injection during surgery [10 μg/kg intravenously, 0. 15 μg/(kg· min) with intravenous pump for 36 h]. Clinical efficacies of 2 groups were compared. The changes of serum inflammatory factors (TNF-α, IL-6, IL-10) and renal function indexes (Scr, CysC, eGFR), the incidence of radiographic contrast nephropathy were compared before surgery and 24, 72 h after surgery. The occurrence of cardiovascular events was followed up for one year. RESULTS: There were no statistical significance in baseline information between 2 groups before treatment (P>0. 05). The number of complete remission case and total response rate in observation group were increased significantly higher than control group (P<0. 05), while number of invalid cases was significantly lower than control group (P<0. 05). Compared with before surgery, the levels of serum inflammation factor in 2 groups were decreased significantly 24, 72 h after surgery, while the levels of Scr and CysC were increased significantly in control group 24, 72 h after surgery and in observation group 24 h after surgery; the level of eGFR was decreased significantly, while the level of CysC was increased significantly in observation group 72 h after surgery, with statistical significance (P<0. 05). The improvement of serum inflammation factors and renal function indexes in observation group were more significant than control group (P<0. 05); the incidence of radiographic contrast nephropathy was significantly lower than control group (P<0. 05). The incidence of 1-year angina pectoris and total incidence of cardiovascular events were significantly lower than control group (P< 0. 05). CONCLUSIONS: Rosuvastatin combined with tirofiban can promote the recovery of renal function in acute coronary syndrome patients with diabetes after PCI, reduce the levels of serum inflammatory factors and decrease the incidence of radiographic contrast nephropathy and post-treatment cardiac events. Its effects are different from rosuvastatin alone.
RESUMO
Objective To evaluate the value of ischemia modified albumin (IMA) in the diagnosis of coronary heart disease (CHD) and the correlation between IMA levels and the pathological scope of coronary atherosclerosis .Methods A total of 88 coro-nary heart disease(CHD) patients diagnosed by coronary arteriongraphy (CAG) were selected ,including stable angina pectoris (16 cases)(SA group) and acute coronary syndrome (72 cases)(ACS group) .ACS group was further divided into 3 groups :unstable an-gina pectoris(30 cases)(UA group) ,non-ST-elevation myocardial infarction (19 cases) (NSTEMI group) ,ST-elevation myocardial infarction(23 cases) (STEMI group) .According to the results of CAG ,CHD patients were divided into 3 groups:1 vessel lesion group ,2 vessels lesion group and 3 vessels lesion group ,and 60 healthy physical cases were selected as control group .Results IMA in the CHD group was significantly higher than in control group (P<0 .05) .IMA in the ACS group was higher than SA group (P<0 .05) .IMA in the NSTEMI group and STEMI group were significantly higher than UA group (P<0 .05) .IMA levels and the degree of coronary atherosclerosis were significantly positively correlated (P<0 .05 ,r=0 .570) .When the cut-off value of IMA was 80 .10 U/mL ,the area under the curve was 0 .869 ,the specificity was 98 .4% and the sensitivity was 65 .9% .Logistic regression a-nalysis showed that IMA was an independent predictor of CHD .Conclusion IMA has a high negative predictive value in the diag-nosis of CHD ,there was a significantly positive correlation between IMA level and the pathological scope of coronary atherosclero-sis .
